Influence of HPV16 E2 and its localisation on the expression of matrix metalloproteinase-9

International Journal of Oncology

Volumn 37, Issue 2, 2010, Pages 337-345

  Mühlen, Sabrina ^a,c   Behren, Andreas ^a,d   Iftner, Thomas ^b   Simon, Christian ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

^d LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

Author keywords

AP 1; E2; Extracellular regulated kinase; Human papillomavirus 16; Matrix metalloproteinase 9

Indexed keywords

ACTIN; GELATINASE B; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; NUCLEAR PROTEIN; TRANSCRIPTION FACTOR AP 1; VIRUS PROTEIN; DNA BINDING PROTEIN; E2 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16; ONCOPROTEIN;

ANIMAL CELL; ARTICLE; CANCER INVASION; CANCER MODEL; CONTROLLED STUDY; COTTONTAIL RABBIT PAPILLOMAVIRUS; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; METASTASIS; MOUSE; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DNA INTERACTION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; RABBIT; SIGNAL TRANSDUCTION; SKIN CARCINOGENESIS; UTERINE CERVIX CANCER; AMINO ACID SEQUENCE; ANIMAL; CELL CULTURE; CELL STRAIN 3T3; CELL TRANSFORMATION; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; METABOLISM; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PHYSIOLOGY; TISSUE DISTRIBUTION;

AMINO ACID SEQUENCE; ANIMALS; BASE SEQUENCE; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; MAP KINASE KINASE 1; MATRIX METALLOPROTEINASE 9; MICE; MITOGEN-ACTIVATED PROTEIN KINASE 3; MOLECULAR SEQUENCE DATA; NIH 3T3 CELLS; ONCOGENE PROTEINS, VIRAL; SIGNAL TRANSDUCTION; TISSUE DISTRIBUTION; TRANSCRIPTION FACTOR AP-1; TRANSFECTION;

EID: 77954167893     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000682     Document Type: Article

References (52)

1. Bosch FX, Lorincz A, Munoz N, Meijer CJ and Shah KV: The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 55: 244-265, 2002. (Pubitemid 34293391)
2. Gillison ML, Koch WM, Capone RB, et al: Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 92: 709-720, 2000.
3. Shamanin V, zur Hausen H, Lavergne D, et al: Human papillomavirus infections in nonmelanoma skin cancers from renal transplant recipients and nonimmunosuppressed patients. J Natl Cancer Inst 88: 802-811, 1996.
4. Giri I and Yaniv M: Structural and mutational analysis of E2 trans-activating proteins of papillomaviruses reveals three distinct functional domains. EMBO J 7: 2823-2829, 1988.
5. Sakai H, Yasugi T, Benson JD, Dowhanick JJ and Howley PM: Targeted mutagenesis of the human papillomavirus type 16 E2 transactivation domain reveals separable transcriptional activation and DNA replication functions. J Virol 70: 1602-1611, 1996. (Pubitemid 26062919)
6. Sedman T, Sedman J and Stenlund A: Binding of the E1 and E2 proteins to the origin of replication of bovine papillomavirus. J Virol 71: 2887-2896, 1997. (Pubitemid 27119930)
7. McBride AA, Romanczuk H and Howley PM: The papillomavirus E2 regulatory proteins. J Biol Chem 266: 18411-18414, 1991.
8. Klaes R, Woerner SM, Ridder R, et al: Detection of high-risk cervical intraepithelial neoplasia and cervical cancer by amplification of transcripts derived from integrated papillomavirus oncogenes. Cancer Res 59: 6132-6136, 1999.
9. Koskinen WJ, Chen RW, Leivo I, et al: Prevalence and physical status of human papillomavirus in squamous cell carcinomas of the head and neck. Int J Cancer 107: 401-406, 2003.
10. Desaintes C, Demeret C, Goyat S, Yaniv M and Thierry F: Expression of the papillomavirus E2 protein in HeLa cells leads to apoptosis. EMBO J 16: 504-514, 1997. (Pubitemid 27067780)
11. Massimi P, Pim D, Bertoli C, Bouvard V and Banks L: Interaction between the HPV-16 E2 transcriptional activator and p53. Oncogene 18: 7748-7754, 1999. (Pubitemid 30052759)
12. Webster K, Parish J, Pandya M, Stern PL, Clarke AR and Gaston K: The human papillomavirus (HPV) 16 E2 protein induces apoptosis in the absence of other HPV proteins and via a p53-dependent pathway. J Biol Chem 275: 87-94, 2002. (Pubitemid 30038957)
13. Blachon S, Bellanger S, Demeret C and Thierry F: Nucleocytoplasmic shuttling of high risk human Papillomavirus E2 proteins induces apoptosis. J Biol Chem 280: 36088-36098, 2005. (Pubitemid 41633880)
14. Jeckel S, Huber E, Stubenrauch F and Iftner T: A transactivator function of cottontail rabbit papillomavirus E2 is essential for tumor induction in rabbits. J Virol 76: 11209-11215, 2002. (Pubitemid 35231275)
15. Behren A, Simon C, Schwab RM, et al: Papillomavirus E2 protein induces expression of the matrix metalloproteinase-9 via the extracellular signal-regulated kinase/activator protein-1 signaling pathway. Cancer Res 65: 11613-11621, 2005.
16. Davidson B, Goldberg I, Kopolovic J, et al: Expression of matrix metalloproteinase-9 in squamous cell carcinoma of the uterine cervix-clinicopathologic study using immunohisto-chemistry and mRNA in situ hybridization. Gynecol Oncol 72: 380-386, 1999.
17. Ikebe T, Shinohara M, Takeuchi H, et al: Gelatinolytic activity of matrix metalloproteinase in tumor tissues correlates with the invasiveness of oral cancer. Clin Exp Metastasis 17: 315-323, 1999.
18. Dumas V, Kanitakis J, Charvat S, Euvrard S, Faure M and Claudy A: Expression of basement membrane antigens and matrix metalloproteinases 2 and 9 in cutaneous basal and squamous cell carcinomas. Anticancer Res 19: 2929-2938, 1999.
19. Westermarck J and Kahari VM: Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J 13: 781-792, 1999.
20. Muhlen S, Behren A, Iftner T, Plinkert PK and Simon C: AP-1 and ERK1 but not p38 nor JNK is required for CRPV early protein 2-dependent MMP-9 promoter activation in rabbit epithelial cells. Virus Res 139: 100-105, 2009.
21. Bakiri L, Matsuo K, Wisniewska M, Wagner EF and Yaniv M: Promoter specificity and biological activity of tethered AP-1 dimers. Mol Cell Biol 22: 4952-4964, 2002. (Pubitemid 34620427)
22. Ozanne BW, Spence HJ, McGarry LC and Hennigan RF: Transcription factors control invasion: AP-1 the first among equals. Oncogene 26: 1-10, 2007.
23. Downward J: Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 3: 11-22, 2003. (Pubitemid 37328883)
24. Harding A, Tian T, Westbury E, Frische E and Hancock JF: Subcellular localization determines MAP kinase signal output. Curr Biol 15: 869-873, 2005. (Pubitemid 40689407)
25. Piao C, Jin M, Kim HB, et al: Ribonucleotide reductase small subunit p53R2 suppresses MEK-ERK activity by binding to ERK kinase 2. Oncogene (In press).
26. Cohen-Armon M, Visochek L, Rozensal D, et al: DNA-independent PARP-1 activation by phosphorylated ERK2 increases Elk1 activity: a link to histone acetylation. Mol Cell 25: 297-308, 2007. (Pubitemid 46127778)
27. Dong Z, Crawford HC, Lavrovsky V, et al: A dominant negative mutant of jun blocking 12-O-tetradecanoylphorbol-13-acetate-induced invasion in mouse keratinocytes. Mol Carcinog 19: 204-212, 1997. (Pubitemid 27360138)
28. Crusius K, Auvinen E and Alonso A: Enhancement of EGF-and PMA-mediated MAP kinase activation in cells expressing the human papillomavirus type 16 E5 protein. Oncogene 15: 1437-1444, 1997. (Pubitemid 27437833)
29. Newberry EP, Willis D, Latifi T, Boudreaux JM and Towler DA: Fibroblast growth factor receptor signaling activates the human interstitial collagenase promoter via the bipartite Ets-Ap1 element. Mol Endocrinol 11: 1129-1144, 1997. (Pubitemid 27278835)
30. Rangatia J, Vangala RK, Singh SM, et al: Elevated c-Jun expression in acute myeloid leukemias inhibits C/EBPalpha DNA binding via leucine zipper domain interaction. Oncogene 22: 4760-4764, 2003. (Pubitemid 36976452)
31. Mathas S, Hinz M, Anagnostopoulos I, et al: Aberrantly expressed c-Jun and JunB are a hallmark of Hodgkin lymphoma cells, stimulate proliferation and synergize with NF-kappa B. EMBO J 21: 4104-4113, 2002. (Pubitemid 34857442)
32. Pacheco MM, Kowalski LP, Nishimoto IN and Brentani MM: Differential expression of c-jun and c-fos mRNAs in squamous cell carcinoma of the head and neck: associations with uPA, gelatinase B, and matrilysin mRNAs. Head Neck 24: 24-32, 2002.
33. Johnson R, Spiegelman B, Hanahan D and Wisdom R: Cellular transformation and malignancy induced by ras require c-jun. Mol Cell Biol 16: 4504-4511, 1996. (Pubitemid 26251252)
34. Smith LM, Wise SC, Hendricks DT, et al: cJun overexpression in MCF-7 breast cancer cells produces a tumorigenic, invasive and hormone resistant phenotype. Oncogene 18: 6063-6070, 1999.
35. Grant S, Freemerman AJ, Birrer MJ, et al: Effect of 1-beta- Darabinofuranosylcytosine on apoptosis and differentiation in human monocytic leukemia cells (U937) expressing a c-Jun dominant-negative mutant protein (TAM67). Cell Growth Differ 7: 603-613, 1996.
36. Shimizu Y, Kinoshita I, Kikuchi J, et al: Growth inhibition of non-small cell lung cancer cells by AP-1 blockade using a cJun dominant-negative mutant. Br J Cancer 98: 915-922, 2008. (Pubitemid 351341616)
37. Jin X, Song X, Li L, et al: Blockade of AP-1 activity by dominant-negative TAM67 can abrogate the oncogenic phenotype in latent membrane protein 1-positive human nasopharyngeal carcinoma. Mol Carcinog 46: 901-911, 2007. (Pubitemid 350058410)
38. Liu Y, Ludes-Meyers J, Zhang Y, et al: Inhibition of AP-1 transcription factor causes blockade of multiple signal transduction pathways and inhibits breast cancer growth. Oncogene 21: 7680-7689, 2002. (Pubitemid 35398814)
39. Young MR, Farrell L, Lambert P, Awasthi P and Colburn NH: Protection against human papillomavirus type 16-E7 oncogene-induced tumorigenesis by in vivo expression of dominant-negative c-jun. Mol Carcinog 34: 72-77, 2002. (Pubitemid 34606509)
40. Li JJ, Rhim JS, Schlegel R, Vousden KH and Colburn NH: Expression of dominant negative Jun inhibits elevated AP-1 and NF-kappaB transactivation and suppresses anchorage independent growth of HPV immortalized human keratinocytes. Oncogene 16: 2711-2721, 1998. (Pubitemid 28279336)
41. Zayzafoon M, Abdulkadir SA and McDonald JM: Notch signaling and ERK activation are important for the osteomimetic properties of prostate cancer bone metastatic cell lines. J Biol Chem 279: 3662-3670, 2004.
42. Al-Ayoubi A, Tarcsafalvi A, Zheng H, Sakati W and Eblen ST: ERK activation and nuclear signaling induced by the loss of cell/matrix adhesion stimulates anchorage-independent growth of ovarian cancer cells. J Cell Biochem 105: 875-884, 2008.
43. Branca M, Ciotti M, Santini D, et al: Activation of the ERK/MAP kinase pathway in cervical intraepithelial neoplasia is related to grade of the lesion but not to high-risk human papillomavirus, virus clearance, or prognosis in cervical cancer. Am J Clin Pathol 122: 902-911, 2004.
44. Cirillo G, Casalino L, Vallone D, Caracciolo A, De Cesare D and Verde P: Role of distinct mitogen-activated protein kinase pathways and cooperation between Ets-2, ATF-2, and Jun family members in human urokinase-type plasminogen activator gene induction by interleukin-1 and tetradecanoyl phorbol acetate. Mol Cell Biol 19: 6240-6252, 1999.
45. Ozanne BW, Spence HJ, McGarry LC and Hennigan RF: Invasion is a genetic program regulated by transcription factors. Curr Opin Genet Dev 16: 65-70, 2006.
46. Favata MF, Horiuchi KY, Manos EJ, et al: Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem 273: 18623-18632, 1998.
47. Cartin W and Alonso A: The human papillomavirus HPV2a E5 protein localizes to the Golgi apparatus and modulates signal transduction. Virology 314: 572-579, 2003.
48. Crusius K, Rodriguez I and Alonso A: The human papillomavirus type 16 E5 protein modulates ERK1/2 and p38 MAP kinase activation by an EGFR-independent process in stressed human keratinocytes. Virus Genes 20: 65-69, 2000.
49. Xie J, Pan H, Yoo S and Gao SJ: Kaposi's sarcoma-associated herpesvirus induction of AP-1 and interleukin 6 during primary infection mediated by multiple mitogen-activated protein kinase pathways. J Virol 79: 15027-15037, 2005.
50. Benn J, Su F, Doria M and Schneider RJ: Hepatitis B virus HBx protein induces transcription factor AP-1 by activation of extracellular signal-regulated and c-Jun N-terminal mitogen-activated protein kinases. J Virol 70: 4978-4985, 1996.
51. Yoshizaki T, Sato H, Furukawa M and Pagano JS: The expression of matrix metalloproteinase 9 is enhanced by Epstein-Barr virus latent membrane protein 1. Proc Natl Acad Sci USA 95: 3621-3626, 1998.
52. O-Charoenrat P, Rhys-Evans PH and Eccles SA: Expression of matrix metalloproteinases and their inhibitors correlates with invasion and metastasis in squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 127: 813-820, 2001.